Recent advances in proteomically subtyping pancreatic ductal adenocarcinomas and their potential clinical impact

Expert Review of Proteomics

Volumn 12, Issue 1, 2014, Pages 5-8

  Roesli, Christoph ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Biomarker Discovery Center Heidelberg   (Germany)

Author keywords

clinical impact; pancreatic ductal adenocarcinoma; proteomics; subtype stratification; tumor heterogeneity

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; PROTEOME; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC TEST; EARLY DIAGNOSIS; ELECTROSURGERY; HISTOPATHOLOGY; HUMAN; MASS SCREENING; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; METASTASIS POTENTIAL; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PROTEOMICS; RADIOSENSITIVITY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; CARCINOMA, PANCREATIC DUCTAL; METABOLISM; PANCREATIC NEOPLASMS;

CARCINOMA, PANCREATIC DUCTAL; HUMANS; PANCREATIC NEOPLASMS; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84921529772     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2015.983478     Document Type: Review

References (26)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in. 2012. Eur J Cancer 2013;49(6):1374-403
2. Werner J, Combs SE, Springfeld C, et al. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol 2013;10(6): 323-33
3. Lewis R, Drebin JA, Callery MP, et al. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford) 2013;15(1):49-60
4. Osayi SN, Bloomston M, Schmidt CM, et al. Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: a review. Biomed Res Int 2014;2014:468959
5. Distler M, Aust D, Weitz J, et al. Precursor lesions for sporadic pancreatic cancer: panIN, IPMN, and MCN. Biomed Res Int 2014;2014:474905
6. Harsha HC, Kandasamy K, Ranganathan P, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009;6(4):e1000046
7. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012; 3(2):105-19
8. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33(3):266-70
9. Datta J, Vollmer CM Jr. Investigational biomarkers for pancreatic adenocarcinoma: where do we stand? South Med J 2014; 107(4):256-63
10. Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res 2012;18(16):4266-76
11. Chan A, Diamandis EP, Blasutig IM. Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics 2013;81: 126-34
12. Tonack S, Jenkinson C, Cox T, et al. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. Br J Cancer 2013;108(9):1846-53
13. Hruban RH, Rustgi AK, Brentnall TA, et al. Pancreatic cancer in mice and man: the Penn Workshop. 2004. Cancer Res 2006;66(1):14-17
14. Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature 2013;501(7467):355-64
15. Heiser LM, Sadanandam A, Kuo WL, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 2012;109(8):2724-9
16. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17(4): 500-3
17. Eisen C, Engelhardt J, Rigo-Watermeier T, et al. Subtype-specific models of pancreatic ductal adenocarcinoma reveal signaling pathways that can be exploited therapeutically. Presented at the 22nd Biennial Congress of the EACR. Eur J Cancer 2012;48(Suppl 5):abstract 306
18. Novel biomarkers for sub-typing pancreatic ductal adenocarcinoma. WO2014056626A1
19. Neubert P, Walch A. Current frontiers in clinical research application of MALDI imaging mass spectrometry. Expert Rev Proteomics 2013;10(3):259-73
20. Norris JL, Caprioli RM. Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. Chem Rev 2013;113(4):2309-42
21. Munteanu B, Hopf C. Emergence of whole-cell MALDI-MS biotyping for high-throughput bioanalysis of mammalian cells? Bioanalysis 2013;5(8):885-93
22. Balog J, Sasi-Szabo L, Kinross J, et al. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci Transl Med 2013;5(194): 194ra193
23. Zawadzka AM, Schilling B, Cusack MP, et al. Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma. Mol Cell Proteomics 2014;13(4):1034-49
24. Choi DS, Kim DK, Kim YK, et al. Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics 2013;13(10-11):1554-71
25. Simona F, Laura S, Simona T, et al. Contribution of proteomics to understanding the role of tumor-derived exosomes in cancer progression: state of the art and new perspectives. Proteomics 2013; 13(10-11):1581-94
26. Mapstone M, Cheema AK, Fiandaca MS, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014;20(4):415-18